Antithrombotic Strategies With Left Ventricular Assist Devices

Area of Science:

• Cardiology
• Biomedical Engineering
• Pharmacology

Background:

• Left ventricular assist devices (LVADs) improve long-term outcomes in advanced heart failure.
• Improved pump engineering enhances LVAD durability and hemocompatibility.
• Adverse events like pump thrombosis, stroke, and bleeding are device-specific.

Purpose of the Study:

• To review current anticoagulation management strategies for LVAD patients.
• To highlight advances in pump technology and their impact on adverse events.
• To discuss the need for further research in LVAD therapy.

Main Methods:

• Review of current literature on LVADs and anticoagulation.
• Analysis of device-specific adverse event profiles.
• Evaluation of modified antithrombotic strategies.

Main Results:

• Fully magnetically levitated rotor LVADs reduce thrombosis and stroke risk.
• Modified anticoagulation (reduced-dose VKAs, DOACs) shows safety and reduces mucosal bleeding.
• Elimination of antiplatelet agents contributes to reduced bleeding events.

Conclusions:

• Anticoagulation management in LVAD patients is evolving with new therapies.
• Careful application of emerging technologies and therapies is necessary.
• Continued research is essential for optimizing LVAD patient care and outcomes.